| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/06/2004 | CA2293712C Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors |
| 01/02/2004 | EP1375661A1 The role of the N-myc - nm23H1/nm23H2 - cdc42 pathway in proliferation, differentiation and treatment of cancer |
| 01/02/2004 | EP1375520A1 Apoptosis induced by monoclonal antibody anti-Her2 |
| 01/02/2004 | EP1375519A2 Method for affecting cellular function using antibodies |
| 01/02/2004 | EP1375516A2 Method of production of a recombinant polypeptide of the LSR receptor |
| 01/02/2004 | EP1374908A2 Polymer-drug conjugates comprising hydrazide linkers |
| 01/02/2004 | EP1374907A2 Drug transport and delivery system |
| 01/02/2004 | EP1374893A1 Vaccination with immuno-isolated cells producing an immunomodulator |
| 01/02/2004 | EP1374890A2 Thrombopoietin compositions for increasing circulating platelets |
| 01/02/2004 | EP1374889A1 Method of inducing angiogenesis by micro-organs |
| 01/02/2004 | EP1374880A1 An antineoplastic drug |
| 01/02/2004 | EP1374876A1 Method of treating tumor and consignment system of proliferating and processing activated lymphocytes to be used in parallel to pdt |
| 01/02/2004 | EP1374875A2 Pharmaceutical compositons comprising arsenic for the treatment of myelodysplastic syndrome |
| 01/02/2004 | EP1374873A1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy |
| 01/02/2004 | EP1374864A1 Amphiphilic taxane compositions |
| 01/02/2004 | EP1373900A2 Renal cell carcinoma tumor markers |
| 01/02/2004 | EP1373888A2 Method for screening for progesterone receptor isoform-specific ligands |
| 01/02/2004 | EP1373559A2 Identification of neural defects associated with the nucleosomal assembly protein 1l2 gene |
| 01/02/2004 | EP1373543A2 Method for producing pectin hydrolysis products |
| 01/02/2004 | EP1373517A2 Human kinases |
| 01/02/2004 | EP1373505A2 Tri-hybrid melanoma antigen |
| 01/02/2004 | EP1373496A1 Methods for identifying peptides which modulate a biological process |
| 01/02/2004 | EP1373489A2 Human dual specificity protein phosphatase 7-like protein |
| 01/02/2004 | EP1373321A2 Modified antibodies and methods of use |
| 01/02/2004 | EP1373317A2 Nuclear hormone receptor ligand binding domains |
| 01/02/2004 | EP1373316A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373315A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373313A2 Proteins and nucleic acids encoding same |
| 01/02/2004 | EP1373306A2 Cytoskeletion-associated proteins |
| 01/02/2004 | EP1373305A1 Process for producing trunkamide a compounds |
| 01/02/2004 | EP1373303A1 Novel peptide ligands of leukocyte integrins |
| 01/02/2004 | EP1373293A1 Steap-related protein |
| 01/02/2004 | EP1373287A1 Process for obtaining lignan, pharmaceutical compositions and uses thereof |
| 01/02/2004 | EP1373275A2 Highly purified and crystalline form of harringtonine |
| 01/02/2004 | EP1373271A1 Indole derivatives having an inhibitory effect on protein kinases |
| 01/02/2004 | EP1373269A1 Jun kinase inhibitors |
| 01/02/2004 | EP1373263A1 Heterocyclic compounds for aging-related and diabetic vascular complications |
| 01/02/2004 | EP1373262A2 Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors |
| 01/02/2004 | EP1373258A1 Ether derivatives useful as inhibitors of pde4 isozymes |
| 01/02/2004 | EP1373257A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/02/2004 | EP1373255A1 Process for the preparation of imidazole compounds |
| 01/02/2004 | EP1373253A1 Inhibitors of cyclin dependent kinases as anti-cancer agent |
| 01/02/2004 | EP1373252A1 Chemical derivatives and their use as anti-telomerase agent |
| 01/02/2004 | EP1373250A1 Viologen linked acridine based molecule and process for the preparation thereof |
| 01/02/2004 | EP1373249A1 Imidazolidine derivatives, their preparation, and their use as antinflamatory agent |
| 01/02/2004 | EP1373244A2 Substituted benzopyranones as telomerase inhibitors |
| 01/02/2004 | EP1373243A1 Aminoflavone compounds, compositions, and methods of use thereof |
| 01/02/2004 | EP1373242A1 Dimeric isoflavones |
| 01/02/2004 | EP1373240A2 Retinoid x receptor modulators |
| 01/02/2004 | EP1373234A2 Urokinase inhibitors |
| 01/02/2004 | EP1373224A1 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| 01/02/2004 | EP1373223A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 01/02/2004 | EP1373221A2 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 01/02/2004 | EP1373217A1 2-mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors |
| 01/02/2004 | EP1373215A1 Geldanamycin derivative and method of treating cancer using same |
| 01/02/2004 | EP1373205A1 Novel piperidine derivatives as modulators of chemokine receptors |
| 01/02/2004 | EP1373199A2 Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and tnf-alpha converting enzyme (tage) |
| 01/02/2004 | EP1373185A2 Hydrophobic polyamine analogs and methods for their use |
| 01/02/2004 | EP1373182A1 Conjugated unsaturated glyceride mixtures and a method for producing the same |
| 01/02/2004 | EP1372741A2 Morpholino imaging and therapy |
| 01/02/2004 | EP1372739A2 Stabilized therapeutic and imaging agents |
| 01/02/2004 | EP1372737A2 Preparation for the prophylaxis of restenosis |
| 01/02/2004 | EP1372736A2 Anti-neovasculature preparations for cancer |
| 01/02/2004 | EP1372735A2 Conjugate of hydroxyalkyl starch and an active agent |
| 01/02/2004 | EP1372733A2 Pharmaceutical compositions of active polypeptides for enhanced pharmacological activity through oral and parenteral administration |
| 01/02/2004 | EP1372732A1 Enzyme-activated cytostatic conjugates with integrin ligands |
| 01/02/2004 | EP1372724A2 Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| 01/02/2004 | EP1372723A1 Semi-allogenic anti-tumour vaccine with hla haplo-identical antigen-presenting cells |
| 01/02/2004 | EP1372719A2 Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer |
| 01/02/2004 | EP1372717A2 Combination treatment of pancreatic cancer |
| 01/02/2004 | EP1372715A2 Method for treating cancer using a33 specific antibodies and chemotherapeutic agents |
| 01/02/2004 | EP1372704A1 Monocyte-specific particulate delivery vehicle |
| 01/02/2004 | EP1372700A1 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
| 01/02/2004 | EP1372696A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/02/2004 | EP1372694A1 Liposome targeting of matrix metalloproteinase inhibitors |
| 01/02/2004 | EP1372692A2 Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor |
| 01/02/2004 | EP1372691A2 Mucin peptide with immunoenhancing properties |
| 01/02/2004 | EP1372677A1 Antitumor methods and compositions comprising sesquiterpene derivatives |
| 01/02/2004 | EP1372671A2 Methylated promoters for intraductal treatment of breast cancer |
| 01/02/2004 | EP1372670A1 Caloporoside derivatives, methods for the production thereof and their use |
| 01/02/2004 | EP1372669A1 Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| 01/02/2004 | EP1372664A1 Use of certain steroids for treatment of blood cell deficiencies |
| 01/02/2004 | EP1372663A1 Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives |
| 01/02/2004 | EP1372659A1 Substances for use in therapy of diseases that are caused by highly proliferative cells |
| 01/02/2004 | EP1372658A2 Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine |
| 01/02/2004 | EP1372657A2 A method of treating proliferative diseases using eg5 inhibitors |
| 01/02/2004 | EP1372656A1 Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors |
| 01/02/2004 | EP1372655A2 Cathepsin cysteine protease inhibitors |
| 01/02/2004 | EP1372654A2 Quinoline inhibitors of hyak1 and hyak3 kinases |
| 01/02/2004 | EP1372652A2 Combination of a taxane and a cyclin-dependent kinase |
| 01/02/2004 | EP1372651A1 Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity |
| 01/02/2004 | EP1372650A2 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 01/02/2004 | EP1372648A2 Tie2 receptor kinase inhibitors for treating angiogenic diseases |
| 01/02/2004 | EP1372636A2 Metronomic dosing of taxanes for inhibiting tumor growth |
| 01/02/2004 | EP1372635A1 Use of creatine for the amelioration of oxidative stress |
| 01/02/2004 | EP1372634A2 Fumaric acid amides |
| 01/02/2004 | EP1372631A1 Method and formula for anti-tumor and anti-matastatic effect |
| 01/02/2004 | EP1372626A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 01/02/2004 | EP1372571A2 Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds |
| 01/02/2004 | EP1372528A2 Mucosal boosting following parenteral priming |